Incyte Genomics (INCY) Misses Q2 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $122.66 +4.31%
Financial Fact:
Selling, general and administrative: 75.78M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Selling, general and administrative: 75.78M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Incyte Genomics (NASDAQ: INCY) reported Q2 EPS of ($0.41), $0.05 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $19.17 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $108 at Bernstein SocGen Group
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
